Advanced Search: Any Solid Tumor

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

201703028

Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors

201711014

A Phase 1, Multicenter, Dose-escalation and Expansion Study of ARX788 as Monotherapy in Advanced Solid Tumors with HER2-expression or Mutation

201904008

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 in Patients with Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies

201909144

A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 In HLA-A2+ Subjects With MAGE-A4 Positive Tumors

201904006

A multicentre, open-label, non-randomised first in human study of NG-641, an oncolytic transgene expressing adenoviral vector, in patients with epithelial tumours

201911172

A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 in Subjects with Advanced Solid Malignancies including Lymphoma

202003170

Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, alone or in combination with other agents, in Participants with Advanced Tumors

202006132

Phase I/II, Two-Part, Multicenter First-in-Human Study of DS-7300a in Subjects with Advanced Solid Malignant Tumors

201807070

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100)

201905195

A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors